Envestnet Asset Management Inc. Sells 41,369 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Envestnet Asset Management Inc. trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 14.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 244,234 shares of the medical research company's stock after selling 41,369 shares during the quarter. Envestnet Asset Management Inc. owned 0.48% of Charles River Laboratories International worth $45,086,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. EP Wealth Advisors LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $273,000. National Bank of Canada FI lifted its stake in Charles River Laboratories International by 45.4% during the third quarter. National Bank of Canada FI now owns 21,216 shares of the medical research company's stock valued at $4,179,000 after buying an additional 6,627 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its holdings in shares of Charles River Laboratories International by 13.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company's stock worth $3,071,000 after buying an additional 1,882 shares during the period. M&T Bank Corp increased its position in shares of Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock worth $394,000 after acquiring an additional 66 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $966,000. 98.91% of the stock is currently owned by institutional investors.

Remove Ads

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their price target for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company's stock. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average price target of $182.00.

Charles River Laboratories International Stock Down 0.8 %

Shares of NYSE CRL traded down $0.88 during mid-day trading on Tuesday, reaching $105.72. 1,447,986 shares of the company traded hands, compared to its average volume of 873,741. The company's fifty day moving average is $155.52 and its two-hundred day moving average is $176.21. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The stock has a market cap of $5.19 billion, a PE ratio of 704.80, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter last year, the company posted $2.46 earnings per share. The company's revenue for the quarter was down 1.1% compared to the same quarter last year. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).